HERCEPTIN CONCURRENT WITH EXTERNAL BEAM RADIATION -BREAST CANCER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is a phase II study. In a phase II study, doctors are trying to learn whether the therapy they are investigating has an effect on treating cancer. The purpose of this research study is to determine how effective the combination of Herceptin and external beam radiation are on treating breast cancer. Herceptin is a man-made monoclonal antibody directed to the Her-2-neu antigen (protein) which cancer has been found to over-produce. Herceptin has been found to help control metastatic breast cancer in patients that over-produce the Her-2-neu protein. In this study, Herceptin will be used as a radiosensitizer. A radiosensitizer is a drug that increases the responsiveness of the cancer cells to radiation. In this study researchers are trying to see if by giving Herceptin, tumor cells will become more responsive to the radiation. The combination of Herceptin and external beam radiation is experimental, not the standard treatment for this type of breast cancer